Recruitment has been a major problem since the start of the research despite a much larger number of “selected” patients (72% non-selection in Limoges for example). One of the obstacles stems from the application of the criterion of cardiovascular non-inclusion (Patient with unbalanced arterial hypertension and Patient with a history of stroke, myocardial infarction, angina, thrombophlebitis, Raynaud.). The relaxation of these 2 criteria would undoubtedly allow a better recruitment since no serious cardiovascular effect was identified in the 21 patients already included, the quantity of product injected locally is low and the current literature does not seem to demonstrate it. serious systemic cardiovascular effects after ocular injection of bevacizumab. Changes to non-inclusion criteria as follows: -Patient with unbalanced arterial hypertension -Patient with a history of an acute cardiovascular event less than 6 months old and / or progressive such as stroke, myocardial infarction, thrombophlebitis -Patient with a history of angina, Raynaud's syndrome considered unstable This amendment, apppuived by trhe DSMB, has been submitted and approved by the Ethic committee and the Competent authority.